Comparing robotic and traditional laparoscopic surgery for obese patients with early endometrial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of robotic-assisted surgery compared to conventional laparoscopic surgery in morbidly obese patients diagnosed with early-stage endometrial cancer. The study will involve a randomized controlled multicentric approach to determine which minimally invasive surgical technique offers better outcomes in terms of safety and efficacy. Given the rising incidence of endometrial cancer among obese women, this research seeks to address the surgical challenges posed by obesity and improve peri-operative results. The trial will include patients with a BMI of 30 or higher and will assess various surgical parameters and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* BMI \>=30
* Age \> 18
* Histologically confirmed endometrioid endometrial cancer
* Clinical early stage (stage I)
* No contraindication for minimally invasive surgery
* ASA\<4
* Written informed consent.

Exclusion Criteria:

* High probability of laparotomy related to uterine volume (US estimated weight \>250 g)
* Concomitant pelvic disease, or anatomical characteristics of the patient
* (Use of uterine manipulator)
* Age \>75 years

Where it's running

• Policlinico Gemelli IRCCS
  Rome, Italy Recruiting

Study contacts

• Principal investigator: Francesco Fanfani, MD — Policlinico Gemelli IRCCS
• Study coordinator: Francesco Fanfani, MD
• Email: francesco.fanfani@policlinicogemelli.it
• Phone: 0630153421

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• PF-08634404 plus chemotherapy in adults with advanced or recurrent pMMR endometrial cancer

  This study tests whether PF-08634404 added to standard chemotherapy helps adults with advanced or recurrent pMMR endometrial cancer more than pembrolizumab plus chemotherapy.

  Recruiting at 47 sites Phase 3 Pfizer · Jupiter, Florida and 53 other locations · NCT07578649

• Molecular and cellular analysis of uterine lavage from gynecologic surgery

  This will try a new uterine lavage catheter to collect samples from up to 50 adults having gynecologic surgery to see what cells are present.

  Recruiting Stanford University · Palo Alto, California · NCT07044505

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Combining Carboplatin, Paclitaxel, and Pembrolizumab for Advanced Endometrial Cancer

  This study is testing a new combination of drugs for people with advanced endometrial cancer to see if it helps them live longer without their cancer getting worse.

  Recruiting at 6 sites Phase 2 Yonsei University · Kyeonggi-do and 5 other locations · NCT06502743

• 3D printed applicators for treating gynecologic cancers

  This study is testing whether 3D-printed custom applicators can make radiation treatment more effective for patients with gynecologic cancers.

  Recruiting Royal North Shore Hospital · St Leonards, New South Wales · NCT06432478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.